Match!
Laura Menotti
University of Bologna
VirologyReceptorHerpes simplex virusOncolytic virusBiology
32Publications
17H-index
1,096Citations
What is this?
Publications 30
Newest
#1Laura MenottiH-Index: 17
#2Valerio LeoniH-Index: 8
view all 8 authors...
Source
#1Andrea VanniniH-Index: 7
#2Biljana PetrovicH-Index: 5
Last. Tatiana GianniH-Index: 15
view all 8 authors...
Source
#1Francesco Alessandrini (UniGe: University of Genoa)H-Index: 3
#2Laura Menotti (UNIBO: University of Bologna)H-Index: 17
Last. Paolo Malatesta (UniGe: University of Genoa)H-Index: 15
view all 8 authors...
Oncolytic herpes simplex viruses are proving to be effective in clinical trials against a number of cancers. Here, R-115, an oncolytic herpes simplex virus retargeted to human erbB-2, fully virulent in its target cells, and armed with murine interleukin-12 was evaluated in a murine model of glioblastoma. We show that a single R-115 injection in established tumors resulted, in about 30% of animals, in the complete eradication of the tumor, otherwise invariably lethal. The treatment also induced a...
3 CitationsSource
#1Laura Menotti (UNIBO: University of Bologna)H-Index: 17
#2Elisa Avitabile (UNIBO: University of Bologna)H-Index: 21
Last. Gabriella Campadelli-Fiume (UNIBO: University of Bologna)H-Index: 41
view all 6 authors...
Previously, we engineered oncolytic herpes simplex viruses (o-HSVs) retargeted to the HER2 (epidermal growth factor receptor 2) tumor cell specific receptor by the insertion of a single chain antibody (scFv) to HER2 in gD, gH, or gB. Here, the insertion of scFvs to three additional cancer targets—EGFR (epidermal growth factor receptor), EGFRvIII, and PSMA (prostate specific membrane antigen)—in gD Δ6–38 enabled the generation of specifically retargeted o-HSVs. Viable recombinants resulted from t...
5 CitationsSource
#1Patrizia Nanni (UNIBO: University of Bologna)H-Index: 45
#2Valentina Gatta (UNIBO: University of Bologna)H-Index: 28
Last. Pier Luigi Lollini (UNIBO: University of Bologna)H-Index: 53
view all 14 authors...
Oncolytic viruses aim to specifically kill tumor cells. A major challenge is the effective targeting of disseminated tumors in vivo. We retargeted herpes simplex virus (HSV) tropism to HER-2 oncoprotein p185, overexpressed in ovary and breast cancers. The HER-2-retargeted R-LM249 exclusively infects and kills tumor cells expressing high levels of human HER-2. Here, we assessed the efficacy of systemically i.p. delivered R-LM249 against disseminated tumors in mouse models that recapitulate tumor ...
22 CitationsSource
#1E Reisoli (UniGe: University of Genoa)H-Index: 1
#2Eleonora Gambini (UniGe: University of Genoa)H-Index: 5
Last. Paolo MalatestaH-Index: 15
view all 7 authors...
Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice
14 CitationsSource
Herpes simplex viruses (HSVs) have entered clinical trials as oncolytic agents. The following properties make them good candidates. It is a mild pathogen; drugs (Aciclovir) are available to control viral infection; the large genome is amenable to genetic engineering, they can be rendered cancer-specific by deletion of genes, envelope glycoproteins allow the insertion of heterologous ligands to achieve modification of the natural tropism. Genetically modified HSVs have been thoroughly tested in h...
4 CitationsSource
#1Eleonora Gambini (UniGe: University of Genoa)H-Index: 5
#2Elisa ReisoliH-Index: 3
Last. Paolo Malatesta (UniGe: University of Genoa)H-Index: 15
view all 7 authors...
Oncolytic herpes simplex viruses (HSVs) represent a novel frontier against tumors resistant to standard therapies, like glioblastoma (GBM). The oncolytic HSVs that entered clinical trials so far showed encouraging results; however, they are marred by the fact that they are highly attenuated. We engineered HSVs that maintain unimpaired lytic efficacy and specifically target cells that express tumor-specific receptors, thus limiting the cytotoxicity only to cancer cells, and leaving unharmed the n...
34 CitationsSource
#1Pier Luigi Lollini (UNIBO: University of Bologna)H-Index: 53
#2Laura Menotti (UNIBO: University of Bologna)H-Index: 17
Last. Patrizia Nanni (UNIBO: University of Bologna)H-Index: 45
view all 12 authors...
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Oncolytic viruses hold the promise to spare normal cells and to selectively seek and destroy tumor cells within the body. Until now numerous viruses where successfully engineered to confer or enhance tumor selectivity, however the effective targeting of disseminated tumor cells in vivo remains a major hurdle. We have retargeted herpes simpex virus (HSV) through the replacement of key gD sequences with sequences encodin...
Source
#2Laura MenottiH-Index: 17
Last. Pier Luigi LolliniH-Index: 53
view all 6 authors...
1 CitationsSource
123